育龄女性分化型甲状腺癌患者的妊娠全周期管理
作者:
通讯作者:
作者单位:

南方医科大学附属广东省人民医院(广东省医学科学院) 内分泌科,广东 广州 510080

作者简介:

关海霞,南方医科大学附属广东省人民医院(广东省医学科学院)主任医师,主要从事内分泌代谢疾病方面的研究。

基金项目:

广东省人民医院高层次全职引进人才配套科研资助项目(KJ012020629)。


Full-pregnancy-cycle management for women of childbearing age with differentiated thyroid cancer
Author:
Affiliation:

Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou510080, China

  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • | | | |
    摘要:

    随着甲状腺癌发病率的不断攀升,我国育龄女性分化型甲状腺癌(DTC)患者的数量增幅明显。这个群体中的很多人承担繁育后代的使命,故而对DTC的临床管理有更高要求。因此,对育龄女性DTC患者开展妊娠全周期(贯穿备孕、妊娠和产后三个阶段)管理是符合中国国情及时代特征的肿瘤健康管理新模式,对守护母亲和子代围产期以及远期健康意义重大,能切实提高DTC的规范化管理水平和改善患者的生活质量。笔者根据现有的文献和指南,梳理从备孕期到妊娠期和产后期践行妊娠全周期管理的具体做法—在备孕期,避免不必要的延期妊娠,结合生育计划制定DTC的个体化治疗方案,做好孕前指导;在妊娠期,继续做好促甲状腺激素(TSH)抑制治疗,指导妊娠期间的甲状腺激素治疗用药,适度进行甲状腺功能和DTC病情的监测和随访;在产后期,理解TSH抑制治疗在哺乳期的安全性,关注产后甲状腺炎的发生及其对甲状腺激素治疗的影响。期待这个领域能够被多学科的更多学者所关注,共同行动,做好数据积累和长期随访,优化妊娠全周期管理的具体策略和路径,与时俱进地为目标人群提供最佳医疗服务。

    Abstract:

    With the rising incidence of thyroid cancer, the number of women of childbearing age diagnosed with differentiated thyroid cancer (DTC) in China has significantly increased. Many in this group bear the responsibility of reproduction, which necessitates higher standards for the clinical management of DTC. Therefore, implementing full-pregnancy-cycle management (encompassing preconception, pregnancy, and postpartum phases) for women of childbearing age with DTC represents a new model of cancer health management tailored to China's national conditions and contemporary characteristics. This approach is of great significance in safeguarding the perinatal and long-term health of mothers and offspring, improving the standardization of DTC management, and enhancing patients' quality of life. Based on existing literature and guidelines, the authors outline specific practices for implementing full-pregnancy-cycle management, spanning the preconception, pregnancy, and postpartum phases. During the preconception phase, unnecessary delays in conception should be avoided, individualized treatment plans for DTC should be developed in alignment with reproductive goals, and thorough pre-pregnancy counseling should be provided. In the pregnancy phase, the focus is on continuing thyrotropin (TSH) suppressive therapy, guiding appropriate thyroid hormone medication use during pregnancy, and monitoring and following up on thyroid function and DTC progression. In the postpartum phase, it is essential to understand the safety of TSH suppressive therapy during lactation, monitor for the occurrence of postpartum thyroiditis, and address its impact on thyroid hormone therapy. It is hoped that this field will garner greater attention from multidisciplinary scholars, fostering collaboration to accumulate data, conduct long-term follow-up, and optimize specific strategies and pathways for full-pregnancy-cycle management, thereby promptly ensuring the best medical services to the target population.

    网友评论
    网友评论
    分享到微博
    发 布
    参考文献
    [1] Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1):1-9. doi:10.1016/j.jncc.2022.02.002.
    [2] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158. doi:10.1016/S0140-6736(19)30427-1.
    [3] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. doi:10.1016/j.jncc.2024.01.006.
    [4] Galofré JC. Thyroid cancer incidence: the discovery of the hidden iceberg[J]. Endocrinol Diabetes Nutr, 2017, 64(6):285-287. doi:10.1016/j.endinu.2017.04.001.
    [5] Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res, 2016, 28(1):1-11. doi:10.3978/j.issn.1000-9604.2016.02.08.
    [6] Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019-2021: a multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4(3):203-213. doi:10.1016/j.jncc.2024.06.005.
    [7] Smith LH, Danielsen B, Allen ME, et al. Cancer associated with obstetric delivery: results of linkage with the California cancer registry[J]. Am J Obstet Gynecol, 2003, 189(4):1128-1135. doi:10.1067/s0002-9378(03)00537-4.
    [8] Mazzaferri EL. Approach to the pregnant patient with thyroid cancer[J]. J Clin Endocrinol Metab, 2011, 96(2):265-272. doi:10.1210/jc.2010-1624.
    [9] Rakhlin L, Fish S, Tuttle RM. Response to therapy status is an excellent predictor of pregnancy-associated structural disease progression in patients previously treated for differentiated thyroid cancer[J]. Thyroid, 2017, 27(3):396-401. doi:10.1089/thy.2016.0501.
    [10] Hirsch D, Levy S, Tsvetov G, et al. Impact of pregnancy on outcome and prognosis of survivors of papillary thyroid cancer[J]. Thyroid, 2010, 20(10):1179-1185. doi:10.1089/thy.2010.0081.
    [11] Leboeuf R, Emerick LE, Martorella AJ, et al. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors[J]. Thyroid, 2007, 17(6):543-547. doi:10.1089/thy.2007.0020.
    [12] Ito Y, Miyauchi A, Kudo T, et al. Effects of pregnancy on papillary microcarcinomas of the thyroid re-evaluated in the entire patient series at Kuma hospital[J]. Thyroid, 2016, 26(1):156-160. doi:10.1089/thy.2015.0393.
    [13] Xi C, Zhang Q, Song HJ, et al. Pregnancy does not affect the prognoses of differentiated thyroid cancer patients with lung metastases[J]. J Clin Endocrinol Metab, 2021, 106(8):e3185-e3197. doi:10.1210/clinem/dgab111.
    [14] Shan R, Li X, Tao M, et al. Pregnancy and the disease recurrence of patients previously treated for differentiated thyroid cancer: a systematic review and meta analysis[J]. Chin Med J (Engl), 2024, 137(5):547-555. doi:10.1097/CM9.0000000000003008.
    [15] Xiao WC, Li X, Shan R, et al. Pregnancy and progression of differentiated thyroid cancer: a propensity score-matched retrospective cohort study[J]. J Clin Endocrinol Metab, 2024, 109(3):837-843. doi:10.1210/clinem/dgad557.
    [16] Cho GJ, Kim SY, Lee HC, et al. Risk of adverse obstetric outcomes and the abnormal growth of offspring in women with a history of thyroid cancer[J]. Thyroid, 2019, 29(6):879-885. doi:10.1089/thy.2018.0283.
    [17] Korevaar TIM, Haymart MR. A history of thyroid cancer does not meaningfully complicate pregnancy[J]. Thyroid, 2019, 29(6):758-759. doi:10.1089/thy.2019.0276.
    [18] Haymart MR, Pearce EN. How much should thyroid cancer impact plans for pregnancy?[J]. Thyroid, 2017, 27(3):312-314. doi:10.1089/thy.2016.0637.
    [19] 胡琳莉, 孙莹璞. 美国妇产科医师学会及美国生殖医学会“与年龄相关的女性生育力减退共识”解读[J]. 中国实用妇科与产科杂志, 2015, 31(8):696-698. doi:10.7504/fk2015070103.Hu LL, Sun YP. Expounding on the consensus of reduced age-related fertility in women by ACOG and American Society for Reproductive Medicine[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2015, 31(8):696-698. doi:10.7504/fk2015070103.
    [20] Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133. doi:10.1089/thy.2015.0020.
    [21] Panagiotakopoulos T, Chorti A, Pliakos I, et al. Thyroid cancer and pregnancy: a systematic ten-year-review[J]. Gland Surg, 2024, 13(6):1097-1107. doi:10.21037/gs-24-52.
    [22] Khaled H, Al Lahloubi N, Rashad N. A review on thyroid cancer during pregnancy: Multitasking is required[J]. J Adv Res, 2016, 7(4):565-570. doi:10.1016/j.jare.2016.02.007.
    [23] Kim HO, Lee K, Lee SM, et al. Association between pregnancy outcomes and radioactive iodine treatment after thyroidectomy among women with thyroid cancer[J]. JAMA Intern Med, 2020, 180(1):54-61. doi:10.1001/jamainternmed.2019.4644.
    [24] Langdon J, Gupta A, Sharbidre K, et al. Thyroid cancer in pregnancy: diagnosis, management, and treatment[J]. Abdom Radiol (NY), 2023, 48(5):1724-1739. doi:10.1007/s00261-023-03808-1.
    [25] 中华医学会内分泌学分会, 中华医学会外科学分会甲状腺及代谢外科学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J]. 中华内分泌代谢杂志, 2023, 39(3):181-226. doi:10.3760/cma.j.cn311282-20221023-00589.Chinese Society of Endocrinology, Thyroid and Metabolic Surgery Group of the Chinese Society of Surgery, Chinese Anti-Cancer Association Head and Neck Tumor Professional Committee, et al. Guidelines for the diagnosis and management of thyroid nodules and differentiated thyroid cancer (Second edition)[J]. Chinese Journal of Endocrinology and Metabolism, 2023, 39(3):181-226. doi:10.3760/cma.j.cn311282-20221023-00589.
    [26] 张淼, 许丹晴, 周力, 等. 影响分化型甲状腺癌术后促甲状腺激素抑制治疗疗效因素的研究进展[J]. 中国普通外科杂志, 2024, 33(6):1012-1017. doi:10.7659/j.issn.1005-6947.2024.06.017.Zhang M, Xu DQ, Zhou L, et al. Factors influencing the efficacy of thyrotropin suppression therapy after surgery for differentiated thyroid cancer: a review of research progress[J]. China Journal of General Surgery, 2024, 33(6):1012-1017. doi:10.7659/j.issn.1005-6947.2024.06.017.
    [27] Yang Y, Guo TL, Fu JR, et al. Preconception thyrotropin levels and risk of adverse pregnancy outcomes in Chinese women aged 20 to 49 years[J]. JAMA Netw Open, 2021, 4(4):e215723. doi:10.1001/jamanetworkopen.2021.5723.
    [28] Yang Y, Guo T, Fu J, et al. Association of preconception thyrotropin levels with fecundability and risk of spontaneous abortion in China[J]. JAMA Netw Open, 2022, 5(8):e2228892. doi:10.1001/jamanetworkopen.2022.28892.
    [29] Kim HI, Jang HW, Ahn HS, et al. High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance[J]. J Clin Endocrinol Metab, 2018, 103(2):446-451. doi:10.1210/jc.2017-01775.
    [30] 关海霞. 从经验到循证, 理性设定分化型甲状腺癌促甲状腺激素抑制治疗目标[J]. 中华内科杂志, 2014, 53(9):694-696. doi:10.3760/cma.j.issn.0578-1426.2014.09.005.Guan HX. From experience to evidence-based, rationally set the target of thyroid stimulating hormone inhibition treatment for differentiated thyroid cancer[J]. Chinese Journal of Internal Medicine, 2014, 53(9):694-696. doi:10.3760/cma.j.issn.0578-1426.2014.09.005.
    [31] 中华医学会地方病学分会, 中国营养学会, 中华医学会内分泌学分会. 中国居民补碘指南[M]. 北京: 人民卫生出版社, 2018:1-33.Chinese Society of Endemic Diseases, Chinese Nutrition Society, Chinese Society of Endocrinology. Iodine supplementation guidelines for Chinese residents[M]. Beijing: People's Medical Publishing House, 2018:1-33.
    [32] 《孕产期甲状腺疾病防治管理指南》编撰委员会, 中华医学会内分泌学分会, 中华预防医学会妇女保健分会. 孕产期甲状腺疾病防治管理指南[J]. 中国妇幼卫生杂志, 2022, 13(4):1-15. doi:10.19757/j.cnki.issn1674-7763.2022.04.001.Writing Committee for Guidelines for Prevention and Management of Thyroid Diseases During Pregnancy and Perinatal Period, Chinese Society of Endocrinology, Women′s Health Care Branch of Chinese Preventive Medicine Association. Guidelines for prevention and management of thyroid diseases during pregnancy and perinatal period[J]. Chinese Journal of Women and Children Health, 2022, 13(4):1-15. doi:10.19757/j.cnki.issn1674-7763.2022.04.001.
    [33] Reigstad MM, Storeng R, Myklebust T?, et al. Cancer risk in women treated with fertility drugs according to parity status-a registry-based cohort study[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(6):953-962. doi:10.1158/1055-9965.EPI-16-0809.
    [34] Brinton LA, Moghissi KS, Scoccia B, et al. Effects of fertility drugs on cancers other than breast and gynecologic malignancies[J]. Fertil Steril, 2015, 104(4):980-988. doi:10.1016/j.fertnstert.2015.06.045.
    [35] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会. 妊娠期和产后分化型甲状腺癌促甲状腺激素抑制治疗中国专家共识(2019版)[J]. 中国实用外科杂志, 2020, 40(3):255-259. doi:10.19538/j.cjps.issn1005-2208.2020.03.05.Chinese Thyroid Association, Specialized Committee of Thyroid Disease of Chinese Research Hospital Association. Chinese expert consensus on post-operative TSH suppression therapy for differentiated thyroid cancer during pregnancy and the postpartum (2019 edition)[J]. Chinese Journal of Practical Surgery, 2020, 40(3):255-259. doi:10.19538/j.cjps.issn1005-2208.2020.03.05.
    [36] 《妊娠和产后甲状腺疾病诊治指南》(第2版)编撰委员会, 中华医学会内分泌学分会, 中华医学会围产医学分会. 妊娠和产后甲状腺疾病诊治指南(第2版)[J]. 中华内分泌代谢杂志, 2019, 35(8):636-665. doi:10.3760/cma.j.issn.1000-6699.2019.08.003.Writing Committee for Guidelines on Diagnosis and Management of Thyroid Diseases during Pregnancy and Postpartum (2nd edition); Chinese Society of Endocrinology, Chinese Medical Association; Chinese Society of Perinatology, Chinese Medical Association. Guideline on diagnosis and management of thyroid diseases during pregnancy and postpartum (2nd edition)[J]. Chinese Journal of Endocrinology and Metabolism, 2019, 35(8):636-665. doi:10.3760/cma.j.issn.1000-6699.2019.08.003.
    [37] Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum[J]. Thyroid, 2017, 27(3):315-389. doi:10.1089/thy.2016.0457.
    [38] Alexander EK, Marqusee E, Lawrence J, et al. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism[J]. N Engl J Med, 2004, 351(3):241-249. doi:10.1056/NEJMoa040079.
    [39] van Wassenaer AG, Stulp MR, Valianpour F, et al. The quantity of thyroid hormone in human milk is too low to influence plasma thyroid hormone levels in the very preterm infant[J]. Clin Endocrinol (Oxf), 2002, 56(5):621-627. doi:10.1046/j.1365-2265.2002.01526.x.
    [40] Guan H, Li C, Li Y, et al. High iodine intake is a risk factor of post-partum thyroiditis: result of a survey from Shenyang, China[J]. J Endocrinol Invest, 2005, 28(10):876-881. doi:10.1007/BF03345318.
    引证文献
引用本文

高日丽,关海霞.育龄女性分化型甲状腺癌患者的妊娠全周期管理[J].中国普通外科杂志,2024,33(11):1759-1765.
DOI:10.7659/j. issn.1005-6947.2024.11.002

复制
分享
文章指标
  • 点击次数:102
  • 下载次数: 691
历史
  • 收稿日期:2024-10-10
  • 最后修改日期:2024-11-19
  • 在线发布日期: 2024-12-18